Y Intercept Hong Kong Ltd Acquires Shares of 271,903 Roivant Sciences Ltd. $ROIV

Y Intercept Hong Kong Ltd acquired a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 271,903 shares of the company’s stock, valued at approximately $3,064,000.

Other institutional investors also recently added to or reduced their stakes in the company. Amundi boosted its holdings in Roivant Sciences by 18.1% in the 1st quarter. Amundi now owns 398,729 shares of the company’s stock valued at $3,991,000 after purchasing an additional 61,214 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Roivant Sciences by 16.3% in the 1st quarter. Bank of New York Mellon Corp now owns 4,000,181 shares of the company’s stock valued at $40,362,000 after purchasing an additional 560,641 shares in the last quarter. Inspire Investing LLC acquired a new stake in shares of Roivant Sciences during the 1st quarter valued at approximately $303,000. GAMMA Investing LLC lifted its position in shares of Roivant Sciences by 83.0% during the 1st quarter. GAMMA Investing LLC now owns 6,493 shares of the company’s stock valued at $66,000 after acquiring an additional 2,945 shares during the period. Finally, Peak Financial Advisors LLC acquired a new stake in shares of Roivant Sciences during the 2nd quarter valued at approximately $472,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Price Performance

Shares of Roivant Sciences stock opened at $18.76 on Thursday. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $18.95. The company has a market capitalization of $12.81 billion, a P/E ratio of -26.80 and a beta of 1.20. The business has a 50 day moving average price of $15.01 and a 200 day moving average price of $12.52.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Citigroup lifted their price target on shares of Roivant Sciences from $16.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday. JPMorgan Chase & Co. lifted their price target on shares of Roivant Sciences from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Thursday, September 18th. Weiss Ratings upgraded shares of Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Saturday, October 25th. Leerink Partners lifted their price objective on Roivant Sciences from $18.00 to $22.00 and gave the stock an “outperform” rating in a research report on Thursday, September 18th. Finally, Jefferies Financial Group lifted their price objective on Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Roivant Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $21.06.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, major shareholder Vivek Ramaswamy sold 1,195,000 shares of the business’s stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $12.50, for a total value of $14,937,500.00. Following the completion of the transaction, the insider directly owned 36,089,108 shares in the company, valued at approximately $451,113,850. The trade was a 3.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Eric Venker sold 683,818 shares of the business’s stock in a transaction on Friday, September 19th. The shares were sold at an average price of $14.95, for a total value of $10,223,079.10. Following the completion of the transaction, the chief executive officer owned 1,969,767 shares of the company’s stock, valued at $29,448,016.65. This trade represents a 25.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 5,228,958 shares of company stock valued at $76,447,638 over the last quarter. 10.80% of the stock is currently owned by insiders.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.